Menu
Back to Journals » Breast Cancer: Targets and Therapy » Volume 8 » default
Breast Cancer: Targets and Therapy
ISSN: 1179-1314
- View all (448)
- Volume 15, 2023 (56)
- Volume 14, 2022 (41)
- Volume 13, 2021 (58)
- Volume 12, 2020 (27)
- Volume 11, 2019 (32)
- Volume 10, 2018 (24)
- Volume 9, 2017 (64)
- Volume 8, 2016 (26)
- Volume 7, 2015 (36)
- Volume 6, 2014 (20)
- Volume 5, 2013 (13)
- Volume 4, 2012 (22)
- Volume 3, 2011 (16)
- Volume 2, 2010 (9)
- Volume 1, 2009 (4)
Archive: Volume 8, 2016
Expression and functionality of TRPV1 in breast cancer cells
Weber LV, Al-Refae K, Wölk G, Bonatz G, Altmüller J, Becker C, Gisselmann G, Hatt H
Breast Cancer: Targets and Therapy 2016, 8:243-252
Published Date: 13 December 2016
Role of natural herbs and phytochemicals to minimize tumor and economic burden in breast cancer treatment
Shoaib M, Ahmed SA
Breast Cancer: Targets and Therapy 2016, 8:241-242
Published Date: 7 December 2016
Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study
Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L
Breast Cancer: Targets and Therapy 2016, 8:231-239
Published Date: 7 December 2016
HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells
Liu W, Ma J, Cheng Y, Zhang H, Luo W, Zhang H
Breast Cancer: Targets and Therapy 2016, 8:223-229
Published Date: 24 November 2016
Tumor suppressor ING4 inhibits estrogen receptor activity in breast cancer cells
Keenen MM, Kim S
Breast Cancer: Targets and Therapy 2016, 8:211-221
Published Date: 17 November 2016
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
Mo QG, Li DQ, Zhong JH, Wei CY
Breast Cancer: Targets and Therapy 2016, 8:207-209
Published Date: 14 November 2016
Statins and risk of breast cancer recurrence
Sakellakis M, Akinosoglou K, Kostaki A, Spyropoulou D, Koutras A
Breast Cancer: Targets and Therapy 2016, 8:199-205
Published Date: 4 November 2016
Current advances in biomarkers for targeted therapy in triple-negative breast cancer
Fleisher B, Clarke C, Ait-Oudhia S
Breast Cancer: Targets and Therapy 2016, 8:183-197
Published Date: 6 October 2016
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
Rashid N, Koh HA, Baca HC, Lin KJ, Malecha SE, Masaquel A
Breast Cancer: Targets and Therapy 2016, 8:173-181
Published Date: 4 October 2016
Reducing infection risk in implant-based breast-reconstruction surgery: challenges and solutions
Ooi ASH, Song DH
Breast Cancer: Targets and Therapy 2016, 8:161-172
Published Date: 1 September 2016
Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about “Triple-negative breast cancer: treatment challenges and solutions” by Collignon et al
Ieni A, Barresi V, Ricciardi GRR, Adamo B, Adamo V, Tuccari G
Breast Cancer: Targets and Therapy 2016, 8:157-159
Published Date: 19 August 2016
Prevalence of CYP2D6*2, CYP2D6*4, CYP2D6*10, and CYP3A5*3 in Thai breast cancer patients undergoing tamoxifen treatment
Charoenchokthavee W, Panomvana D, Sriuranpong V, Areepium N
Breast Cancer: Targets and Therapy 2016, 8:149-155
Published Date: 8 August 2016
Adjuvant systemic therapy in older women with breast cancer
Leone J, Leone BA, Leone JP
Breast Cancer: Targets and Therapy 2016, 8:141-147
Published Date: 25 July 2016
A systematic review and meta-analysis of Harmonic technology compared with conventional techniques in mastectomy and breast-conserving surgery with lymphadenectomy for breast cancer
Cheng H, Clymer JW, Ferko NC, Patel L, Soleas IM, Cameron CG, Hinoul P
Breast Cancer: Targets and Therapy 2016, 8:125-140
Published Date: 18 July 2016
The absence of aldehyde dehydrogenase 1 A1-positive cells in benign mammary stroma is associated with risk factors for breast cancer
Isfoss BL, Holmqvist B, Jernström H, Alm P, Olsson H
Breast Cancer: Targets and Therapy 2016, 8:117-124
Published Date: 27 May 2016
Is radiation-induced ovarian ablation in breast cancer an obsolete procedure? Results of a meta-analysis
Al Asiri M, Tunio MA, Abdulmoniem R
Breast Cancer: Targets and Therapy 2016, 8:109-116
Published Date: 25 May 2016
Triple-negative breast cancer: treatment challenges and solutions
Collignon J, Lousberg L, Schroeder H, Jerusalem G
Breast Cancer: Targets and Therapy 2016, 8:93-107
Published Date: 20 May 2016
Profile of palbociclib in the treatment of metastatic breast cancer
Ehab M, Elbaz M
Breast Cancer: Targets and Therapy 2016, 8:83-91
Published Date: 17 May 2016
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
Yardley DA
Breast Cancer: Targets and Therapy 2016, 8:73-82
Published Date: 3 May 2016
Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent
Hanlon KE, Lozano-Ondoua AN, Umaretiya PJ, Symons-Liguori AM, Chandramouli A, Moy JK, Kwass WK, Mantyh PW, Nelson MA, Vanderah TW
Breast Cancer: Targets and Therapy 2016, 8:59-71
Published Date: 15 April 2016
Breast cancer characteristics in very young Egyptian women ≤35 years
Farouk O, Ebrahim MA, Senbel A, Emarah Z, Abozeed W, Seisa MO , Mackisack S, Abdel Jalil S, Abdelhady S
Breast Cancer: Targets and Therapy 2016, 8:53-58
Published Date: 5 April 2016
Factors affecting local recurrence and distant metastases of invasive breast cancer after breast-conserving surgery in Chiang Mai University Hospital
Ditsatham C, Somwangprasert A, Watcharachan K, Wongmaneerung P, Khorana J
Breast Cancer: Targets and Therapy 2016, 8:47-52
Published Date: 18 March 2016
Astym therapy improves function and range of motion following mastectomy
Davies CC, Brockopp D, Moe K
Breast Cancer: Targets and Therapy 2016, 8:39-45
Published Date: 8 March 2016
Identification and prioritization of candidate genes for symptom variability in breast cancer survivors based on disease characteristics at the cellular level
Koleck TA, Conley YP
Breast Cancer: Targets and Therapy 2016, 8:29-37
Published Date: 8 March 2016
Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer
Casneuf T, Axel AE, King P, Alvarez JD, Werbeck JL, Verhulst T, Verstraeten K, Hall BM, Sasser AK
Breast Cancer: Targets and Therapy 2016, 8:13-27
Published Date: 3 February 2016
Managing breast cancer in younger women: challenges and solutions
Ademuyiwa FO, Cyr A, Ivanovich J, Thomas MA
Breast Cancer: Targets and Therapy 2016, 8:1-12
Published Date: 21 December 2015